Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Eptifibatide

Eptifibatide

GP IIb/IIIa inhibitor (cyclic heptapeptide)

PCIIVAdult

Indication

ACS medical management β€’ PCI adjunct per protocol

At a glance

INDICATIONS (CORE USE)

PCI / ACS infusion β€” **renal dose**; shorter TΒ½ than abciximab.

ADULT DOSE (STANDARD)

Double bolus + infusion per label; **CrCl <50** dose reduction

MAX DOSE

Per label infusion max

Route

IV

PEDIATRIC DOSE

Not used

Do not miss

Must-not-miss safety points

Major warning

- Bleeding with heparin - thrombocytopenia - hypotension with bolus

Indications

USE IF: ACS/PCI per institutional pathway. AVOID IF: Active bleed, dialysis-dependent ESRD (contraindicated per label), severe HTN uncontrolled.

Primary

  • Non-ST elevation ACS
  • PCI when GPI indicated

Dosing

STANDARD (ADULT PO)

180 mcg/kg boluses + 2 mcg/kg/min infusion (adjust if CrCl <50 per label)

ADULT DOSE

Verify weight-based math with pharmacy.

PEDIATRIC DOSE

N/A

MAX DOSE

Label infusion caps

Practical Note

Renal adjustment mandatory CrCl <50; contraindicated dialysis in many labels.

Warnings

Clinical warnings

  • **Major bleeding** (GI, ICH, post-procedural) β€” higher with **DAPT**, triple therapy, renal failure, age β€” counsel early symptoms
  • **Thrombocytopenia** on infusion β€” stop drug; **not** interchangeable monitoring vs oral agents
  • Platelet monitoring
  • PTCA within 12 weeks bleed risk

Adverse effects

  • Bleeding
  • hypotension
  • thrombocytopenia

Contraindications

  • **Active major bleeding** β€” hold until controlled unless embedded in explicit procedural plan
  • **Recent major surgery / ICH** β€” generally **avoid** outside cath-lab ACS/PCI protocol
  • Active abnormal bleeding
  • ESRD dialysis (label)
  • prior hemorrhagic stroke

Drug interactions

  • **Heparin/bivalirudin stack in lab** β†’ bleed surveillance per protocol; **any new antiplatelet** β†’ **reassess** β€” not outpatient casual add-on
  • Heparin
  • oral anticoagulants
  • other inhibitors of platelets

Special populations

Pediatrics

Not used

Pregnancy

Avoid unless necessary

Lactation

See lactation references and product labeling.

Renal impairment

**CrCl <50** reduce dose; dialysis β€” often contraindicated

Hepatic impairment

Limited effect on clearance

Elderly

Renal function estimate critical

Administration

IV dedicated line; cardiac monitoring

Monitoring

  • Monitor: - **Platelet count falls on infusion** β†’ **stop GPI** + hematology - **Access-site or systemic bleed** β†’ **stop infusion** + hemostasis; **abciximab** longer platelet-bound effect than small molecules - **Hypotension with bolus** β†’ slow per protocol - **Transition to oral DAPT** per cath lab β€” **no duplicate** GPI + outpatient antiplatelet stack - Platelet count - aPTT if heparin co-infused
  • Recheck: - New or worsening **bleeding**, unexplained **Hb drop**, or planned invasive procedure within **48–72h** β†’ reassess antiplatelet plan with cardiology/surgery when on DAPT - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**A) Therapeutic complication:** **bleeding** during/after PCI or **thrombocytopenia** on infusion β€” dominant scenarios. **B) True β€œoverdose”** beyond protocol bolus: management is **stop infusion + supportive/bleed care** β€” **no** specific reversal antidote (unlike salicylate toxicology).

Immediate Actions

**A:** Stop infusion β†’ ABCs; **platelet count**; access-site + systemic hemostasis; platelet transfusion if **severe thrombocytopenia + active bleed** per hematology. **B:** Supportive; prolonged monitoring if massive bolus error β€” institution-specific

Antidote

No specific antidote; treat complications (supportive care, platelets / hemostasis per protocol, anaphylaxis β†’ epinephrine per ACLS)

Decontamination

N/A

Escalation

Refractory bleed or platelets **<20k** with hemorrhage β†’ **ICU** + hematology; **short TΒ½** (eptifibatide/tirofiban) vs **abciximab** longer platelet-bound effect

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

**Renal dose** β€” non-negotiable. β†’ Short TΒ½ once stopped.

Clinical pearls

Double bolus + drip β€” verify pump programming. *Antiplatelet (all agents):* **Primary vs secondary (aspirin):** primary **not routine**; secondary **strong** when guideline-supported. **DAPT:** **do not stop early** post-stent without expert; duration **ACS vs stable CAD**; procedures need **explicit review**. **Bleeding-first:** GI/ICH/peri-op; **duplicate/hidden aspirin** on med rec. **Aspirin toxicity** (salicylate) is a **separate pathway** from antiplatelet bleed.

Antiplatelet safety

  • CrCl math
  • Platelets
  • Heparin interaction

Pharmacokinetics

Renal elimination; TΒ½ ~2.5 h β€” offset faster than abciximab.

Mechanism of action

Reversible GP IIb/IIIa blockade.

Common brand names

Saudi Arabia

Integrilin

Global

(placeholder β€” verify local product)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • DAPT duration and perioperative management follow **ESC/AHA/ACC** and local cardiology consensus β€” not one-size rules.
  • Primary prevention aspirin thresholds differ by guideline and age β€” verify regional primary-care policy.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol
  • ACC / AHA / ESC cardiovascular guidelines (CAD, ACS, PCI)
  • FDA / SFDA product labeling
  • Local cath lab / antithrombotic protocol

Do not miss

  • Document antiplatelet indication (primary vs secondary prevention vs stent DAPT)
  • Med reconciliation: OTC aspirin, NSAIDs, fish oil, anticoagulants
  • **Thrombocytopenia:** Acute drop on infusion β†’ **stop GPI** + hematology β€” can mimic HIT timing but pathway differs.
  • **Bleeding (access site / systemic / peri-PCI):** **Stop infusion** + hemostasis; **abciximab** longer platelet-bound effect than **eptifibatide/tirofiban** β€” procedural timing differs.
  • **Duplicate blockade:** GPI + DAPT + parenteral anticoagulant β†’ **maximal bleed** β€” protocol-driven only; **no casual addition** of NSAID/antiplatelet.
  • Dialysis patient β€” **contraindicated** on label.
  • CrCl math
  • Platelets
  • Heparin interaction